← Back
Data updated: Jun 28, 2026
ZEVRA DENMARK
Pharma Pharmaceuticals
ZEVRA DENMARK is a pharmaceutical company with 1 FDA-approved products.
2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2024) 1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Priority Review 1 Fast Track
See 1 novel approval →
2024 MIPLYFFA (ARIMOCLOMOL CITRATE) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
ZEVRA DENMARK's Key Drugs
ZEVRA DENMARK's core commercial portfolio centers on MIPLYFFA — its most strategically important drugs approved in the last 15 years.
ZEVRA DENMARK's Recent FDA Approvals
ZEVRA DENMARK secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ZEVRA DENMARK's Therapeutic Areas
Disease areas where ZEVRA DENMARK has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ZEVRA DENMARK Pipeline Snapshot
Active clinical trials for ZEVRA DENMARK across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MIPLYFFA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-09-20
- Latest
- 2024-09-20
- Applications
- 1